Anima Biotech is a recognized leader in small molecule mRNA drugs. Backed by our strategic collaborations with Lilly, Takeda and Abbvie, our mRNA lightning™ platform is bringing AI to mRNA biology. With our proprietary visualization technologies, we have generated over 2 billion images of the mRNA life cycle in cells and train disease-specific image neural networks that visually recognize the mRNA regulatory pathways underlying disease mechanisms. With our tera-scale platform, we conduct millions of massively parallel automated biology experiments, screening for active molecules that revert the images of diseased cells back to a healthy phenotype. Our MOAi technology uses mRNA biology knowledge graph, LLM, and the Lightning co-pilot to identify their mechanisms of actions and molecular targets.
Anima's wholly owned disclosed pipeline of mRNA biology modulators is in Immunology (Lung fibrosis candidate advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Lymphoma and Neuroblastoma), in Neuroscience (Alzheimer's disease and Pain).
In addition to our own pipeline, we established strategic collaborations with Pharma in the discovery of mRNA drugs, targets, and vaccines.
Career Opportunities
Weizmann Alumni who work here
